Bacillus anthracis is a causative agent of the highly mortal disease anthrax. This zoonosis is present in nature, but it is also considered one of the most powerful biological warfare agents. A timely diagnosis is necessary for proper therapy and setting of epidemiological countermeasures. Current diagnostic methods should be used in specialized laboratories or medical facilities because there are only a limited number of methods suitable as hand-held assays or even point-of-care tests for detecting B. anthracis or anthrax diagnosis. The lateral flow tests are an exception in this regard, but these tests also have some limitations. Significant progress has been achieved in point-of-care tests for B. anthracis detection and anthrax diagnosis in various biosensors and bioassays. This review focuses on current hand-held and point-of-care tests that can easily prove anthrax or its causative agent outside the context of specialized facilities.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/0109298673310620240704132204 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analgesic Self-medication Among Patients With Chronic Musculoskeletal Pain in a South African Chiropractic Teaching Clinic: A Cross-sectional Study.
J Chiropr Med
March 2024
Department of Basic Medical Sciences, Durban University of Technology, Durban, KwaZulu-Natal, South Africa.
Objectives: The purpose of this study was to identify the prevalence of chronic musculoskeletal pain (CMSP) and analgesic self-medication. The knowledge and practices of those who self-medicate with analgesics and factors influencing this was also ascertained.
Methods: This study was a quantitative, descriptive cross-sectional study.
Prediction of post-contrast acute kidney injury by bedside ultrasonography.
BMC Emerg Med
January 2025
Department of Emergency Medicine, Recep Tayyip Erdoğan University Training and Research Hospital, Rize, 53020, Turkey.
Background: The incidence of contrast-induced acute kidney injury (CI-AKI) in the general population ranges from 0.6 to 2.3%, whereas for specific high-risk patients, the incidence can reach more than 30-40%.
View Article and Find Full Text PDFDiagnostic performance of prehospital EFAST in predicting CT scan injuries in severe trauma patients: a multicenter cohort study.
Eur J Trauma Emerg Surg
January 2025
Department of Emergency Medicine, Assistance publique des hôpitaux de Marseille (APHM), Marseille University, Timone University Hospital, Marseille, France.
Background: The early mortality of trauma patients, mainly from hemorrhagic shock, raises interest in detecting the presence of non-exteriorized bleeding. Intra-hospital EFAST (Extended Focused Assessment with Sonography for Trauma) has demonstrated its utility in the assessment and management of severe trauma patients (STP). However, there is a lack of data regarding the diagnostic performance of prehospital EFAST (pEFAST).
View Article and Find Full Text PDFRecent developments and future directions in point-of-care next-generation CRISPR-based rapid diagnosis.
Clin Exp Med
January 2025
Department of Zoology, Faculty of Science, Ain Shams University, Abbassia, Cairo, 11566, Egypt.
The demand for sensitive, rapid, and affordable diagnostic techniques has surged, particularly following the COVID-19 pandemic, driving the development of CRISPR-based diagnostic tools that utilize Cas effector proteins (such as Cas9, Cas12, and Cas13) as viable alternatives to traditional nucleic acid-based detection methods. These CRISPR systems, often integrated with biosensing and amplification technologies, provide precise, rapid, and portable diagnostics, making on-site testing without the need for extensive infrastructure feasible, especially in underserved or rural areas. In contrast, traditional diagnostic methods, while still essential, are often limited by the need for costly equipment and skilled operators, restricting their accessibility.
View Article and Find Full Text PDFQuantitative determination of leptin hormone using gold nanoparticle-based lateral flow assay.
Mikrochim Acta
January 2025
Science and Technology Research and Application Center (BITAM), Necmettin Erbakan University, Konya, Türkiye.
A lateral flow assay (LFA) has been developed that can be used in point-of-care (PoC) use for the sensitive determination of leptin hormone. The limit of detection value was 0.158 ng/mL and the limit of quantification value was 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!